Skip to main content

Advertisement

SpringerLink
Log in

A Strategy to Identify Stable Membrane-Permeant Peptide Inhibitors of Myosin Light Chain Kinase

  • Rapid Communication
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose.

A peptide inhibitor of myosin light chain kinase (MLCK), termed membrane permeant inhibitor of myosin light chain kinase (PIK), has previously been demonstrated to correct paracellular barrier defects associated with in vitro cell models of infectious and inflammatory intestinal disease. The current study describes a strategy to identify stable analogues of PIK required for future in vivo studies that has resulted in the identification of two promising candidates.

Methods.

Because PIK functions at an intracellular site of epithelial cells and is envisaged to be administered orally, hydrolysis patterns were determined for PIK in both extracts of homogenized Caco-2 (a human intestinal epithelial cell line) and in luminal secretions isolated from rat intestine. Based on these hydrolysis patterns, four peptides Ac-RKKYKYRRK-NH2 (acetylated PIK), rkkykyrrk-NH2 (D PIK), krrykykkr-NH2 (Dreverse PIK), and RKKykyRRK-NH2 (Dpalindrome PIK) were synthesised. Studies were carried out to determine the stability, activity, and selectivity of these PIK analogues.

Results.

D PIK and Dreverse PIK had much longer half-lives of 3.6 and 13.4 h, respectively, compared to PIK, acetylated (Ac)-PIK, or Dpalindrome PIK. All PIK analogues inhibited MLCK potently, although D PIK was a slightly better inhibitor than the other analogues. Similarly, all PIK analogues enhanced paracellular barrier function in Caco-2 monolayers studied in vitro. No appreciable inhibition of cAMP-dependent protein kinase (PKA) or calcium/calmodulin-dependent protein kinase II (CaMPKII) was detected with any of the analogues.

Conclusions.

PIK is quickly degraded within two enzyme-containing preparations that represent different aspects of the intestinal environment. The PIK analogues D PIK and Dreverse PIK demonstrated extended half-lives in these enzyme preparations while retaining the biological activity and specificity of the parent PIK peptide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CD:

Crohn disease

GVHD:

graft-versus-host disease

IBD:

inflammatory bowel disease

MLCK:

myosin light chain kinase

PIK:

membrane permeant inhibitor of myosin light chain kinase

TER:

transepithelial electrical resistance

UC:

ulcerative colitis

References

  1. 1. D. R. Clayburgh, L. Shen, and J. R. Turner. A porous defence: the leaky epithelial barrier in intestinal disease. Lab. Invest. 84:282–291 (2004).

    PubMed  Google Scholar 

  2. 2. G. Bouma and W. Strober. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521–522 (2003).

    PubMed  Google Scholar 

  3. 3. E. Carty and D. S. Rampton. Evaluation of new therapeutics for inflammatory bowel disease. Br. J. Clin. Pharmacol. 56:351–361 (2003).

    PubMed  Google Scholar 

  4. 4. G. R. May, L. R. Sutherland, and J. B. Meddings. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology 104:1627–1632 (1993).

    PubMed  Google Scholar 

  5. 5. J. R. Turner. ‘Putting the squeeze‘ on tight junctions: understanding cytoskeletal regulation. Semin. Cell. Dev. Biol. 11:301–308 (2000).

    PubMed  Google Scholar 

  6. 6. J. R. Turner, B. K. Rill, S. L. Carlson, D. Carnes, R. Kerner, R. J. Mrsny, and J. L. Madara. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am. J. Physiol. 273:C1378–C1385 (1997).

    PubMed  Google Scholar 

  7. 7. Y. Zolotarevsky, G. Hecht, A. Koutsouris, D. E. Gonzalez, C. Quan, J. Tom, R. Mrsny, and J. R. Turner. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123:163–172 (2002).

    PubMed  Google Scholar 

  8. 8. P. G. Heyworth, R. W. Erickson, J. Ding, J. T. Curnutte, and J. A. Badway. Napthalenesulphoamides block neutrophil superoxide production by intact cells and in cell-free system: is myosin light chain kinase responsible for these effects? Biochem. J. 311:81–87 (1995).

    PubMed  Google Scholar 

  9. 9. T. J. Lukas, S. Mirzoevea, U. Slomezynska, and D. M. Watterson. Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J. Med. Chem. 42:910–919 (1999).

    PubMed  Google Scholar 

  10. 10. T. R. Soderling and J. T. Stull. Structure and regulation of calcium/calmodulin-dependent protein kinases. Chem. Rev. 101:2341–2351 (2001).

    PubMed  Google Scholar 

  11. 11. M. Ikebe, M. Stepinska, B. E. Kemp, A. R. Means and D. J. Hartshorne. Proteolysis of smooth muscle myosin light chain kinase. Formation of inactive and calmodulin-independent fragments. J. Biol. Chem. 262:13828–13843 (1987).

    PubMed  Google Scholar 

  12. 12. J. J. Berglund, M. Riegler, Y. Zolotarevsky, E. Wenzl, and J. R. Turner. Regulation of human jejunal transmucosal resistance and MLC phosphorylation by Na+-glucose cotransport. Am. J. Physiol.—Gastrointest. Liver Physiol. 281:G1487–1493 (2001).

    PubMed  Google Scholar 

  13. 13. R. B. Pearson, J. R. Woodgett, P. Cohen, and B. R. Kemp. Substrate specificity of a multifunctional calmodulin-dependent protein kinase. J. Biol. Chem. 260:14471–14476 (1985).

    PubMed  Google Scholar 

  14. 14. J. R. Turner, J. M. Angle, E. D. Black, J. L. Joyal, D. B. Sacks, and J. L. Madara. Protein kinase C-dependent regulation of transepithelial resistance: the roles of myosin light chain and myosin light chain kinase. Am. J. Physiol. 277:C554–C562 (1999).

    PubMed  Google Scholar 

  15. 15. M. Chorev and M. Goodman. Recent developments in retro peptides and proteins – an ongoing topochemical exploration. Trends Biotechnol. 13:438–445 (1995).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, UK

    Siân-Eleri Owens, Dario Siccardi & Randall J. Mrsny

  2. Department of Pathology, University of Chicago, Chicago, Illinois

    W. Vallen Graham & Jerrold R. Turner

Authors
  1. Siân-Eleri Owens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Vallen Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Siccardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jerrold R. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Randall J. Mrsny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siân-Eleri Owens.

Additional information

Note: This revised article was published online in June 2005. Both authors Owens and Graham contributed equally.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Owens, SE., Graham, W., Siccardi, D. et al. A Strategy to Identify Stable Membrane-Permeant Peptide Inhibitors of Myosin Light Chain Kinase. Pharm Res 22, 703–709 (2005). https://doi.org/10.1007/s11095-005-2584-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-005-2584-9

Key words:

Search

Navigation